Vaxart Announces Preliminary Results of Annual Meeting of Stockholders
SOUTH SAN FRANCISCO, Calif., June 13, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (“Vaxart” or the “Company”),…
0,459$
1,64%
Echtzeit-Aktienkurs Vaxart
Bid:
Ask:
Nachrichten zur Vaxart Aktie
Vaxart to Host Conference Call on June 11 at 8:30 AM ET to Discuss Topline Results from Its Phase I Norovirus Trial
SOUTH SAN FRANCISCO, Calif., June 10, 2025 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT), a clinical-stage biotechnology company…
Vaxart, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”)…
Oral Vaccine Focused Penny Stock Vaxart Is Uniquely Positioned, Analyst Sees Almost 83% Upside
Oppenheimer initiated coverage on Vaxart Inc. (NASDAQ:VXRT), an American biotechnology company focused on the discovery, development, and commercialization of oral…
Vaxart, Inc. (VXRT) Q2 2024 Earnings Call Transcript
…
Vaxart Inc: Asymmetric Risk-Reward Opportunity Following BARDA Funding
…
Vaxart Announces $40 Million Underwritten Offering of Common Stock
SOUTH SAN FRANCISCO, Calif., June 13, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (“Vaxart”) (Nasdaq: VXRT) today announced an…
Vaxart, Inc. (VXRT) Q1 2024 Earnings Call Transcript
…
Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript
…